| Literature DB >> 28927576 |
Kirsty J McMillan1, Tracey K Murray2, Nora Bengoa-Vergniory3, Oscar Cordero-Llana1, Jane Cooper2, Amy Buckley4, Richard Wade-Martins3, James B Uney1, Michael J O'Neill2, Liang F Wong1, Maeve A Caldwell5.
Abstract
Abnormal alpha-synuclein (α-synuclein) expression and aggregation is a key characteristic of Parkinson's disease (PD). However, the exact mechanism(s) linking α-synuclein to the other central feature of PD, dopaminergic neuron loss, remains unclear. Therefore, improved cell and in vivo models are needed to investigate the role of α-synuclein in dopaminergic neuron loss. MicroRNA-7 (miR-7) regulates α-synuclein expression by binding to the 3' UTR of the Synuclein Alpha Non A4 Component of Amyloid Precursor (SNCA) gene and inhibiting its translation. We show that miR-7 is decreased in the substantia nigra of patients with PD and, therefore, may play an essential role in the regulation of α-synuclein expression. Furthermore, we have found that lentiviral-mediated expression of miR-7 complementary binding sites to stably induce a loss of miR-7 function results in an increase in α-synuclein expression in vitro and in vivo. We have also shown that depletion of miR-7 using a miR-decoy produces a loss of nigral dopaminergic neurons accompanied by a reduction of striatal dopamine content. These data suggest that miR-7 has an important role in the regulation of α-synuclein and dopamine physiology and may provide a new paradigm to study the pathology of PD.Entities:
Keywords: Parkinson’s disease; lentiviral vector; microRNA; microRNA-7; α-synuclein
Mesh:
Substances:
Year: 2017 PMID: 28927576 PMCID: PMC5628933 DOI: 10.1016/j.ymthe.2017.08.017
Source DB: PubMed Journal: Mol Ther ISSN: 1525-0016 Impact factor: 11.454